decrease in contractile elements, myofilament disarray, and interstitial fibrosis. Recently, the activation of signal transduction pathways that trigger the onset of programmed cell death has been implicated in promoting this pathological transition, as well as a gp130-depen- cycling defects in the transition to heart failure, the Heart failure, the leading cause of combined morbidity current study employed a genetic complementation and mortality in the United States and other developed strategy in a well-characterized mouse model of dilated nations, is a complex disease in which genetic pathways cardiomyopathy, which harbors a deficiency in a cytoskelthat confer susceptibility are interwoven with the envietal protein, the muscle-specific LIM protein (MLP) (Arber ronmental stimulus of biomechanical stress (Hunter and et al., 1997). The present report demonstrates that the Chien, 1999). In response to this biomechanical stress, progressive defects in EC coupling in dilated cardiomya series of parallel and converging signaling pathways opathy are related to the enhanced inhibition of SERare activated that lead to the adaptive response of comCA2a by PLB, and it shows that inhibition of either PLB pensatory hypertrophy (Chien et al., 1999) . Subsequently, expression or PLB-SERCA2a interaction can prevent there can be a transition to chamber dilation and pump heart failure. failure that is associated with a loss of viable myocytes, a
and characteristics of both the PLBKO and MLPKO mice have been previously described in detail elsewhere (Luo et al., 1994; Arber et al., 1997). As described in Experimental Procedures, the F4 generation of these mice was used for the current studies to eliminate any potential background effects from either the PLBKO or MLPKO line on the observed cardiac phenotype of the double MLP/PLB knockout (DKO) line. MLPKO mice displayed a marked increase in heart:body weight ratio (6.34 Ϯ 0.22 mg/g, n ϭ 8) versus age-and gender-matched wildtype mice (4.60 Ϯ 0.21 mg/g, n ϭ 7; p Ͻ 0.001). The heart:body weight ratio in DKO mice (5.13 Ϯ 0.19 mg/g, n ϭ 9) was significantly smaller than that of MLPKO mice (p Ͻ 0.01). Histological analyses of hearts from MLPKO and DKO littermates showed that ablation of PLB in the background of MLP Ϫ/Ϫ mice rescued the wide spectrum of morphological and ultrastructural defects originally observed in the MLP-deficient hearts, including chamber dilation, myofibrillar disarray, and massive fibrosis (Arber et al., 1997; Figure 1 ). These data suggest that ablation of PLB prevents not only the increase in total heart mass, but also the disorganization of cardiomyocyte cytoarchitecture and fibrosis in MLPKO cardiomyopathic mice. Interestingly, this latter effect on inhibition of fibrosis was not observed in parallel studies (Rockman et al., 1998) employing transgenic mice that express an inhibitory peptide for the ␤-adrenergic receptor kinase (Koch et al. 1995) . While the basis for this discrepancy is unclear, it may reflect the mosaic expression of the transgene versus the uniform deletion of PLB in the present study.
PLB Ablation Rescues In Vivo Cardiac Function in MLPKO Mice
To determine whether the marked decreases observed in in vivo global cardiac function are rescued in DKO mice, echocardiography was performed with agematched littermates. As noted in Figure 2A , prevention of ventricular dilation was confirmed in DKO mice. MLPKO mice had enlarged cardiac chambers, as re- echocardiographic data in DKO mice were similar to those in wild-type mice, although heart rate was slightly decreased in DKO mice ( recombination in mice can augment cardiac contractile intact anesthetized mice. Several independent hemodynamic parameters document the rescue of the severe performance to a level comparable to that with maximal ␤-adrenergic stimulation of the normal heart (Luo et al., cardiac dysfunction with circulatory congestion to normal levels in the DKO mice. LV contractility (assessed 1994). To determine whether ablation of PLB can reverse the hemodynamic defects and marked ␤-adrenergic reby LV dP/dtmax) and relaxation (assessed by LVdP/ dtmin) at baseline in the DKO mice was significantly ceptor desensitization associated with dilated cardiomyopathy, we performed cardiac catheterization in larger than that of wild-type mice and was comparable Figure 3D ). Quantitative immunobloture 2D). Tau, an indicator of LV relaxation and diastolic function, was also normalized in the DKO mice ( Figure  ting revealed that MLP deficiency did not cause any significant alterations in protein levels of SERCA2a, PLB, 2E), which is consistent with a marked reduction in wall stress. These data suggest that ablation of PLB can calsequestrin ( Figure 3E ), ryanodine receptors, and L-type Ca 2ϩ channels (data not shown), suggesting that rescue both the systolic and diastolic dysfunction in the cardiomyopathic MLPKO mice. The suprarescue effects the defects of Ca 2ϩ cycling in MLPKO mice result from functional impairment of EC coupling, as opposed to on contractility and relaxation were maintained over the long term, as assessed by hemodynamic analysis in a simply reflecting decreases in the protein levels of Ca 2ϩ cycling. subset of DKO (n ϭ 5) and MLPKO (n ϭ 4) mice at 8 months of age ( Table 2) .
The blunted responses of LV dP/dtmax and LVdP/ Rescue of Embryonic Gene Markers of the Heart Failure Phenotype in DKO Mice dtmin to ␤-adrenergic stimulation were observed in MLPKO mice ( Figures 2F and 2G ), indicating the presOne of the characteristic features of heart failure is the reactivation of an embryonic gene program, which may ence of severe ␤-adrenergic desensitization in MLPKO mice. There was no stimulation of cardiac contractility contribute to a compensatory response to an increased hemodynamic load (Chien et al., 1993) . Ventricles of (LV dP/dtmax) and relaxation (LV dP/dtmin) to dobutamine in DKO mice ( Figures 2F and 2G ). These parameters MLPKO mice displayed a 26-fold increase in ANF, a 13-fold increase in ␣-skeletal actin, and an 8-fold enhancewere already stimulated to their maximal levels under basal conditions in the DKO hearts. In fact, after maximent of ␤-MHC mRNAs ( Figure 3F ). Strikingly, DKO mice exhibited only a 1.9-fold increase in ANF, and no signifimum stimulation of wild-type hearts by dobutamine, LV dP/dtmax and LV dP/dtmin were indistinguishable from cant increase in ␣-skeletal actin or ␤-MHC mRNAs. Thus, ablation of PLB largely suppresses induction of these parameters in the DKO mice in the absence of any catecholamine stimulation. In summary, these results the embryonic gene program in MLPKO mice. suggest that the interaction of PLB and SERCA2a suppresses cardiac contractility in both normal and myoInhibition of the Interaction between PLB and SERCA2a Dominantly Activates pathic hearts, and that inhibiting this interaction may exert a dominant effect on maximizing cardiac perforCardiac Contractility To define the molecular mechanism of the rescue effect, mance in the absence of any catecholamine stimulation. Chronotropic responsiveness to dobutamine was preit was necessary to assess whether the chronic interaction of PLB and SERCA2a is indeed limiting for cardiac served in both DKO mice and MLPKO mice ( Figure 2I ), thereby documenting the specificity of the ␤-adrenergic contractility in both normal and myopathic hearts. Representative data of myocyte contraction. Myocytes that overexpress the V49A point mutation in PLB display increased contractility, while myocytes that overexpress the wildtype PLB exhibit decreased contractility when compared to noninfected myocytes. also been shown to converge on cytoskeletal pathways be based upon a known inhibitor of SERCA2a, PLB, we attempted to genetically complement the onset of (Badorff et. al. 1999) . The mechanisms that link cytoskeletal defects with the onset of chamber dilation and dilated cardiomyopathy and progression to overt heart failure in the MLP-deficient mice by generating strains the associated decreases in cardiac contractility and relaxation are unclear. The nature of the downstream that harbor a double mutation in both of these musclespecific genes, MLP and PLB. Remarkably, the double molecular pathways that account for defects in excitation-contraction coupling in failing cardiac myocytes is knockout mice display a rescue of the entire spectrum of the MLP-deficient heart failure phenotype at the strucunknown. Presumably, since calcium cycling is critical for both cardiac relaxation and contractility, defects in tural, functional, and molecular level. These studies have been independently supported by our recent studies of the pathways that control calcium uptake and release from the SR are prime candidates for driving the pro-MLP-deficient mice harboring a transgene which directs cardiac-specific overexpression of SERCA2a, that also gression of heart failure. However, direct evidence for their causal relationship in the progression of heart failexhibit rescue of the cardiomyopathy phenotype (unpublished observations). ure and dilated cardiomyopathy has been lacking.
To -calmodulinclearly document that the removal of the inhibitory influence of PLB not only restores cardiac contractility and dependent kinase, the regulation of cardiac contractility by cyclic AMP-dependent stimuli may occur via the relaxation, but leads to suprarescue of cardiac contractility in a manner indistinguishable from those observed phosphorylation of PLB, which in turn prevents the inhibitory interaction with SERCA2a. According to this view, in our current study. Thus, in other independent models of cardiomyopathy, the tonic inhibition of PLB on the the "suprarescue" of the cardiomyopathic MLP-deficient mice to supernormal levels in the setting of PLB SR Ca ATPase pump appears to be central for the progression of in vivo cardiac dysfunction and associated deficiency might simply reflect the removal of the ratelimiting step in the tonic inhibition of cardiac contractildecreases in contractility. Taken together, these results provide the clearest evidence to date that SR calcium ity. Consistent with this notion, recent studies employing transgenic mice that overexpress an inhibitory peptide cycling is critical to the progression of heart failure and point to the critical regulatory role of PLB inhibition of for the ␤-adrenergic receptor kinase (Koch et al. 1995) have documented that relief of ␤-adrenergic desensitiSERCA2a activity in the onset of heart failure in the setting of dilated cardiomyopathy. zation in the MLP-deficient mice can also lead to significant rescue of the dilated cardiomyopathic phenotype Recently, a number of parallel and converging signaling pathways have been discovered that lead to cardio-(Rockman et al., 1998). Since PLB is an SR protein that interacts with at least three regulatory components (the myopathy and heart failure (Chien, 1999). There are a number of distinct genetic and environmental stimuli cyclic AMP-dependent protein kinases, Ca 2ϩ -calmodulindependent protein kinases, and protein phosphatases), that can lead to various forms of heart failure, and, as a result, there are likely to be a number of positive and it became critical to determine whether this dominant effect of PLB ablation on improving cardiac contractile negative modifiers of the complex heart failure phenotype. In fact, studies in MLP-deficient mice have docuperformance reflects the chronic interaction of PLB with the SERCA2a or whether this rescue effect is related to mented independent genetic background effects that can promote and suppress the phenotype, leading to the interaction of PLB with other known or novel cardiac proteins. To directly address this point, we created point wide alterations in the onset of the phenotype (Arber et al., 1997). The possibility exists that distinct complemenmutations in PLB that can interrupt the normal inhibitory interaction between PLB and SERCA2a. Our mutagenetation groups will arise that may uncover new pathways which will modify the course of the disease. In addition, sis strategy was based upon previous studies by MacLennan and coworkers, which carefully identified the an analogous genetic complementation strategy should also prove useful in determining whether PLB inhibition precise residues in PLB that are required for maintaining its interaction with SERCA proteins (Toyofuku et al., is a critical modifier of other forms of dilated cardiomyopathy and heart failure. In this regard, a cardiac-1994; Kimura et al., 1997, 1998). Utilizing recombinant adenoviruses that force the expression of wild-type, and restricted knockout of a gp130-dependent myocyte survival pathway has already been shown to be an immutant forms of PLB, we document that the point mutaportant genetic modifier of acquired forms of heart failtions that selectively interrupt PLB-SERCA2a interacure following exposure to the biomechanical stress of tions can dominantly activate cardiac contractility in pressure overload (Hirota et al., 1999 ). It will also become cardiac ventricular muscle cells in the absence of cateof interest to determine whether PLB ablation would be cholamines. Taken together, these results demonstrate capable of rescuing heart failure that arises as a result that the progressive defects in EC coupling and heart of extrinsic signals. 
